REMARKS

Applicant gratefully acknowledge the courtesy shown by the Examiner in a telephone conference on January 13, 2000.

Claims 44 and 47 have been amended to recite that an adjuvant is administered with the haptenized human tumor cell composition when used in a method of treating a malignant numor. This amendment is supported amply in the specification, e.g., at page 12, line 27 (co-administering) and page 14, lines 15-16 (adjuvant) and the claims, e.g., canceled claims 63 and 73 respectively.

This amendment is believed to place the claims in condition for allowance.

Terminal Disclaimer

Accompanying this Amendment is a terminal disclaimer of any patent issuing from this application in view of U.S. Patent No. 5,290,551 to Bird, issued March 1, 1994.

Information Disclosure Statement

Applicants respectfully request that the Examiner return the PTO 1449 Form filed on December 1, 1998, which disclosed U.S. Patent 5,484,596 to Hanna et al.

CONCLUSION

Applicant respectfully requests entry of the foregoing amendment and remarks in the file history of the above-identified application. The claims as amended are believed to

meet the statutory criteria for patentability. If there are any issues, the Examiner is invited to contact the undersigned by telephone. Allowance of the claims is earnestly solicited.

Respectfully submitted,

Paul F. Fehlner, Ph.D.

Reg. No. 35,135

Attorney for Applicant

DARBY & DARBY, P.C. 805 Third Avenue New York, N.Y. 10022 Phone (212) 527-7700

M-\12259C674V\$00x1,WPD